Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study.
hepatitis C virus
hepatitis C-positive donors
kidney transplantation
liver transplantation
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
21
08
2019
revised:
02
11
2019
accepted:
03
12
2019
pubmed:
7
12
2019
medline:
24
6
2021
entrez:
7
12
2019
Statut:
ppublish
Résumé
Transplantation of organs from hepatitis C virus (HCV)-antibody (Ab) and -nucleic acid test (NAT) positive donors into HCV-negative recipients has been proposed to expand the donor pool and shorten waiting times. Data on early single-center outcomes are lacking. Nineteen liver (LT, including seven simultaneous liver-kidney [SLKT]) and 17 kidney transplant (KT) recipients received organs from HCV (+) donors; of these, 13 were HCV NAT (+) in each group. All patients who received organs from HCV NAT (+) donors developed HCV viremia post-transplant except for 2 KT recipients. Patients were treated with a variety of direct-acting antiviral regimens, with high rates of sustained virologic response among those with at least 12 weeks of follow-up past the end of treatment: 12/13 (92%) and 8/8 (100%) among LT/SLKT, and KT recipients. Median time to treatment start was 42 days (interquartile range [IQR] 35-118 days) and 40 days (IQR 26-73) post-LT/SLKT and KT, respectively. One death occurred in a SLKT recipient unrelated to HCV or its treatment. There was no significant increase in rejection, proteinuria, or changes in immunosuppression in any group. Organs from HCV-viremic donors can be utilized for HCV-uninfected recipients with good short-term outcomes.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13761Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2016 annual data report: liver. Am J Transplant. 2018;18(Suppl 1):172-253.
Levitsky J, Formica RN, Bloom RD, et al. The american society of transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17(11):2790-2802.
Bari K, Luckett K, Kaiser T, et al. Hepatitis C transmission from seropositive, non-viremic donors to non-hepatitis C liver transplant recipients. Hepatology. 2017;67(5):1673-1682.
Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999;117(1):149-153.
Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl. 2004;10(9):1120-1130.
Cotter TG, Paul S, Sandıkçı B, et al. Improved Graft Survival after Liver Transplantation for Recipients with Hepatitis C in the Direct-acting Antiviral Era. Liver Transpl. 2019;25(4):598-609.
La Hoz RM, Sandıkçı B, Ariyamuthu VK, Tanriover B. Short-Term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive non-viremic donors and viremic donors in the Era of direct-acting antivirals. Am J Transplant. 2019;Jun:17.
Saxena V, Khungar V, Verna EC, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. Hepatology. 2017;66(4):1090-1101.
Nookala AU, Crismale J, Schiano T, et al. Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver-kidney transplant recipients. Clin Transplant. 2018;32(3):e13198.
Reau N, Kwo PY, Rhee S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology. 2018;68(4):1298-1307.
Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014;59(10):1411-1419.
Hedegaard H, Miniño A, Warner M.Drug Overdose Deaths in the United States, 1999-2017 [Internet]. [cited 2019 Feb 9]. Available from: https://www.cdc.gov/nchs/products/databriefs/db329.htm.
Durand CM, Bowring MG, Thomas AG, et al. The drug overdose epidemic and deceased-donor transplantation in the United States: A National Registry Study. Ann Intern Med. 2018;168(10):702-711.
Cotter TG, Paul S, Sandıkçı B, et al. Increasing utilization and excellent initial outcomes following liver transplant of HCV-Viremic Donors into HCV-Negative Recipients. Hepatology. 2019;69(6):2381-2395.
Gonzalez SA, Trotter JF. The rise of the opioid epidemic and hepatitis C-positive organs: A new era in liver transplantation. Hepatology. 2018;67(4):1600-1608.
Kling CE, Perkins JD, Biggins SW, Johnson CK, Limaye AP, Sibulesky L. Listing practices and graft utilization of hepatitis C-positive deceased donors in liver and kidney transplant. Surgery. 2019;166(1):102-108.
Bowring MG, Kucirka LM, Massie AB, et al. Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era. Am J Transplant. 2017;17(2):519-527.
Kwong AJ, Wall A, Melcher M, et al. Liver Transplantation for HCV Non-Viremic Recipients with HCV Viremic Donors. Am J Transplant. 2018;19(5):1380-1387.
Kapila N, Al-Khalloufi K, Bejarano PA, Vanatta JM, Zervos XB. Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: A unique complication in the DAA era. Am J Transplant. 2019. https://doi.org/10.1111/ajt.15583. [Epub ahead of print].
Okamura K, Kuwabara T, Enoki H, et al. Regression of hepatitis C virus-associated membranoproliferative glomerulonephritis with direct-acting antiviral therapy after liver transplantation. Nephrology. 2019;24(11):1198-1199.
Cannon RM, Locke JE, Orandi BJ, et al. Impact of donor hepatitis C virus on kidney transplant outcomes for hepatitis C positive recipients in the direct acting antiviral era: time to revise the kidney donor risk index? Transplantation. 2019. https://doi.org/10.1097/TP.0000000000002949. [Epub ahead of print].
Reese PP, Abt PL, Blumberg EA, et al. Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial. Ann Intern Med. 2018;169(5):273-281.
Goldberg DS, Abt PL, Blumberg EA, et al. Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. N Engl J Med. 2017;376(24):2394-2395.
Barsoum RS, William EA, Khalil SS. Hepatitis C and kidney disease: A narrative review. J Advanc Res. 2017;8(2):113-130.
Hogan JJ, Lim MA, Palmer MB, Bloom RD, Chung RT, Sise ME. Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection. Hepatology. 2017;66(2):658-660.
Gentil MA, González-Corvillo C, Perelló M, et al. Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study. Transplant Proc. 2016;48(9):2944-2946.
Grabarczyk P, van Drimmelen H, Kopacz A, et al. Head-to-head comparison of two transcription-mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus Type 1 in blood donors. Transfusion. 2013;53(10 Pt 2):2512-2524.